Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220701 · ClinicalTrials.gov registry record · Phase 4
Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
A Phase 4 study, sponsored by St. Luke's-Roosevelt Hospital Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT00220701 is a Phase 4 study that has completed, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 36 participants.
The verdict
NCT00220701, a Phase 4 study, has completed, sponsored by St. Luke's-Roosevelt Hospital Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a 12-week double-blind placebo-controlled study of Escitalopram in treatment of dysthymic Disorder (low-grade chronic depression), with a 12 week open-label extension phase. It is hypothesized that Escitalopram will be superior to placebo in improving depression, as well as psychosocial, temperamental, and cognitive functioning.
Interventions
- DRUG Lexapro (escitalopram)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2002-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00220701
The ClinicalTrials.gov registry entry for NCT00220701 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Luke's-Roosevelt Hospital Center, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lexapro (escitalopram) is the first listed.
NCT00220701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00220701 about?
NCT00220701 is a clinical study titled "Escitalopram in the Treatment of Dysthymic Disorder, Double Blind". This is a 12-week double-blind placebo-controlled study of Escitalopram in treatment of dysthymic Disorder (low-grade chronic depression), with a 12 week open-label extension phase. It is hypothesized that Escitalopram will be superior to placebo in improving depression, as well as psychosocial, te...
What is the current status of trial NCT00220701?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2002-06. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00220701?
The interventions under investigation include: Lexapro (escitalopram) (DRUG).
Who is sponsoring clinical trial NCT00220701?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.